Therapeutic potential of benfotiamine and its molecular targets

dc.contributor.authorRaj, V.
dc.contributor.authorOjha, S.
dc.contributor.authorHowarth, F.C.
dc.contributor.authorBelur, P.D.
dc.contributor.authorSubramanya, S.B.
dc.date.accessioned2026-02-05T09:31:46Z
dc.date.issued2018
dc.description.abstractOBJECTIVE: The water-soluble vitamin, thiamine forms an important part of the diet because of its role in the energy metabolism. The protective effects of thiamine against diabetic vascular complications have been well documented. However, slower absorption and reduced bioavailability is a major limiting factor for its clinical use. To overcome this issue, lipid-soluble derivatives of thiamine (allithiamines) was developed. Among the many synthetic lipophilic derivatives of thiamine, benfotiamine (BFT) is regarded as the first choice based on its safety and clinical efficacy data. BFT facilitates the action of thiamine diphosphate, a cofactor for the enzyme transketolase. The activation of transketolase enzyme accelerates the precursors of advanced glycation end products (AGEs) towards the pentose phosphate pathway thereby reducing the production of AGEs. The reduction in AGEs subsequently decreases metabolic stress which benefits vascular complications seen in diabetes. The effects of BFT on the AGE-dependent pathway is well established. However, several studies have shown that BFT also modulates pathways other than AGE such as arachidonic acid (AA), nuclear transcription Factor ?B (NF-?ß), protein kinase B, mitogen-activated protein kinases (MAPK) and vascular endothelial growth factor receptor 2 (VEGFR2) signaling pathways. In the present review, we have comprehensively reviewed all the molecular targets modulated by BFT to provide mechanistic perspective to highlight its pleiotropic effects. © 2018 Verduci Editore s.r.l. All rights reserved.
dc.identifier.citationEuropean Review for Medical and Pharmacological Sciences, 2018, 22, 10, pp. 3261-3273
dc.identifier.issn11283602
dc.identifier.urihttps://idr.nitk.ac.in/handle/123456789/25360
dc.publisherVerduci Editore s.r.l g.lombardi@verduci.it
dc.subjectadvanced glycation end product
dc.subjectarachidonic acid
dc.subjectbenfotiamine
dc.subjectglycogen synthase kinase 3beta
dc.subjectimmunoglobulin enhancer binding protein
dc.subjectmitogen activated protein kinase
dc.subjectprotein kinase B
dc.subjecttransketolase
dc.subjectvasculotropin C
dc.subjectbenphothiamine
dc.subjectthiamine
dc.subjectapoptosis
dc.subjectArticle
dc.subjectdrug efficacy
dc.subjectdrug safety
dc.subjectdrug structure
dc.subjectdrug targeting
dc.subjectenergy metabolism
dc.subjectenzyme activation
dc.subjectenzyme activity
dc.subjectextracellular matrix
dc.subjecthuman
dc.subjecthyperglycemia
dc.subjectlipophilicity
dc.subjectmetabolic stress
dc.subjectnonhuman
dc.subjectoxidative stress
dc.subjectpentose phosphate cycle
dc.subjectpleiotropy
dc.subjectsignal transduction
dc.subjectthiamine deficiency
dc.subjectanimal
dc.subjectdiabetic angiopathy
dc.subjectdrug effect
dc.subjectAnimals
dc.subjectDiabetic Angiopathies
dc.subjectHumans
dc.subjectSignal Transduction
dc.subjectThiamine
dc.titleTherapeutic potential of benfotiamine and its molecular targets

Files

Collections